Regulatory Roundup: Ethics Group Calls on FTC to Investigate Drug Pricing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: Ethics Group Calls on FTC to Investigate Drug Pricing

ePT--the Electronic Newsletter of Pharmaceutical Technology

The Citizens for Responsibility and Ethics in Washington, a nonprofit organization dedicated to promoting ethics and accountability, sent a letter to the Federal Trade Commission (FTC) on July 6, 2010, asking for the commission to investigate drug companies “that offer significant discounts to doctors for providing patients with only that company’s vaccines.” The organization claims that Sanofi Pasteur and Merck “offer significant price discounts” if healthcare groups agree to buy their vaccines solely from one manufacturer. The organization states that this practice prevents doctors from using alternative vaccines, even when they may better meet patient needs.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here